The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients

Trial Profile

The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2016

At a glance

  • Drugs Dasatinib (Primary) ; Dexamethasone; Methotrexate; Prednisone
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Acronyms TCLDCWTTNDPP
  • Most Recent Events

    • 27 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top